Items of Interest Compiled by Arnold Public Affairs With the beginning of the 82nd Legislature this week, Members are quickly shaking off the sluggishness of the Interim period and gearing up for the 20-week-long regular session ahead. After ambitiously vowing to address major issues such as ... Keep Reading
Archives for January 2011
Jim Arnold will speak at the Annette Strauss Institute for Civic Participation's Executive Communication Training on January 15, 2011. The Executive Communication Training program is geared at professionals interested in improving their communities. This training will focus on practical skills for ... Keep Reading
Ellen Arnold was the guest speaker today at the Round Rock ISD Council of PTAs. As part of her work for the firm, Ellen does a significant amount of advocacy training for non-profit organizations. Speaking to about 100 volunteers, Ellen discussed the 82nd Legislative Session that just began, ... Keep Reading
From Harvey Kronberg's Quorum Report : OGDEN WARNS OF PAINFUL BUDGET CUTS TO COME Medicaid, education programs cannot be spared, the new Senate president pro tem and longtime Finance chairman tells colleagues. Soon after taking the oath as president pro tempore of the Texas Senate, Bryan ... Keep Reading
Items of Interest Compiled by Arnold Public Affairs Only 2 days before the start of the new 82nd Legislature. Here’s what to expect in the next 10 days: Comptroller Combs will issue her revenue estimate so the mystery about how big the shortfall is (ranges from $10b to 28b) will be solved; The ... Keep Reading
I was in Southern Sudan in August 2009 with the International Republican Institute, and the discussion with all the political parties we were working with was about this election. Tomorrow, those in the South will begin to vote to create their own country, separate from the rest of Sudan. While ... Keep Reading
US biotech company Advanced Cell Technology said Monday it was cleared by the government to start its second trial using human embryonic stem cells to treat blindness, this time in older people. The trial will examine the therapy's ability to safely treat people with a condition known as dry ... Keep Reading